Targeting specific mutations in T cell lymphoma for treatment
Selective targeting of a Rho GTPase mutant for peripheral T cell lymphoma treatment
This study is looking for better ways to treat peripheral T cell lymphoma, an aggressive cancer, by using new technology and existing medications to target specific genetic changes in the disease, with the hope of finding more effective treatments for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10873914 on NIH RePORTER |
What this research studies
This research focuses on developing targeted therapies for peripheral T cell lymphoma (PTCL), a type of aggressive cancer that arises from T cells. The team aims to create new treatments by utilizing Proteolysis Targeting Chimera (PROTAC) technology and repurposing existing medications to specifically target genetic mutations found in PTCL patients. By studying genetically modified mouse models that mimic the disease, researchers hope to understand how these mutations drive cancer progression and how to effectively reduce tumor growth. This approach is designed to provide a more effective treatment option for patients suffering from this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with peripheral T cell lymphoma who have specific genetic mutations, particularly in TET2 and RHOA.
Not a fit: Patients with other types of lymphomas or those without the targeted genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatment options for patients with peripheral T cell lymphoma.
How similar studies have performed: Other research has shown promise in targeting specific genetic mutations in cancers, indicating that this approach could be effective.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Zhou, Yubin — Texas A&m University Health Science Ctr
- Study coordinator: Zhou, Yubin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.